The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients
暂无分享,去创建一个
A. Versari | S. Morbelli | G. Sambuceti | M. Bauckneht | F. Bertagna | D. Albano | R. Laudicella | S. Baldari | R. Giubbini | A. Berruti | M. I. Donegani | A. Miceli | R. Durmo | V. De Biasi | G. Fornarini | M. Donegani